ISSCR News
ISSCR Opposes Proposal to Restrict Fetal Tissue Research
The ISSCR, the largest professional organization of stem cell researchers from around the world, opposes the U.S. House of Representatives proposal to ban federal funding for fetal tissue research. ISSCR President Hans Clevers released the following statement…
ISSCR Responds to President Trump Signing 'Right to Try' Law
The ISSCR is disappointed with the enactment of the ‘Right to Try’ law. Along with more than 100 patient and research groups opposing the bill, we believe it will put patients at risk and undermine the effective FDA Expanded Access Program already in place to give seriously ill patients access to experimental treatments.
ISSCR Applauds Federal Injunctions Against Stem Cell Clinics
The ISSCR is pleased that federal prosecutors in the U.S. have taken action to halt the marketing and delivery of unproven stem cell treatments at clinics they allege are operating outside of FDA regulation: California Stem Cell Treatment Center, Cell Surgical Network Corporation, and U.S. Stem Cell Clinic in Florida…
ISSCR Applauds Australia’s Move to Regulate Autologous Human Cell and Tissue Products
The ISSCR appreciates the new framework proposed by Australia’s Therapeutic Goods Administration (TGA) for the regulation of human cell and tissue products that use a person’s own cells (‘autologous use’). These new regulations are meant to halt the marketing and administration of unproven cell therapies that have not been proven safe or effective. Sales of these products by unscrupulous clinics to desperate patients have been increasing in recent years. Recently, these products resulted in the death of an Australian patient and the blinding of three patients in the United States.
Receive ISSCR Press Releases
Sign up be a part of ISSCR’s media list. Media Contact: Kym Kilbourne, Director of Media and Strategic Communications
Subscribe to ISSCR News.
Each month, ISSCR delivers scientific, policy, and community to your inbox .